Published in Medical Letter on the CDC and FDA, November 28th, 2004
The company plans to commence a phase 3 trial of Cloretazine in combination with Ara-C in relapsed acute myelogenous leukemia no later than the first quarter of 2005.
Orphan drug designation may be granted to products that treat rare diseases or conditions that...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.